Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
BörsenkürzelTMCI
Name des UnternehmensTreace Medical Concepts Inc
IPO-datumApr 23, 2021
CEOMr. John T. Treace
Anzahl der mitarbeiter477
WertpapierartOrdinary Share
GeschäftsjahresendeApr 23
Addresse100 Palmetto Park Place
StadtPONTE VEDRA
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl32081
Telefon19043735940
Websitehttps://www.treace.com/
BörsenkürzelTMCI
IPO-datumApr 23, 2021
CEOMr. John T. Treace
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten